Xu

Xu v. FibroGen, Inc.

Good Law
United States District Court, Northern District of CaliforniaAugust 30, 20213:21-cv-02623California8,007 words

Opinion

Trial Court Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 PEIFA XU, Case No. 21-cv-02623-EMC

Plaintiff,

ORDER GRANTING MOTIONS TO

v. CONSOLIDATE; AND GRANTING

RETIREMENT SYSTEMS’ MOTIONS

FIBROGEN, INC., et al., FOR APPOINTMENT AS LEAD

PLAINTIFF AND APPROVAL OF

Defendants. LEAD COUNSEL

Docket Nos. 22, 29,

13 I. INTRODUCTION This case is a securities-fraud class action brought on behalf of investors who purchased stock in FibroGen, Inc., from October 2017 through April 2021. Plaintiffs assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) as well as Securities and Exchange (“SEC”) Rule 10b-5. Pending before the Court are three class members’ motions for consolidation of related actions, appointment as lead plaintiff, and approval of lead counsel pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”). The motions were…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.